Elif ÖZSU, Gul Yesiltepe MUTLU, Filiz Mine ÇİZMECİOĞLU, Rifat BİRCAN, Şükrü HATUN

Two siblings with familial subclinical hyperthyroidism with unknown etiology

Subclinical hyperthyroidism is defined as low or undetectable concentration of serum thyrotrophin (TSH) with normal free triiodothyronine (FT3) and free thyroxine (FT4) levels. 1). Familial subclinical hyperthyroidism is a rare entity. Activating mutations of the TSH receptor (TSH-R) gene cause genetic hyperthyroidism. Here we present a family with more than one affected individual. All family members were investigated for TSH-R mutation. No mutation was detected, while a A459 polymorphism was found in one of the cases and three other siblings. Despite the clinical and biochemical findings suggesting a TSH-R mutation, a reasonable cause could not be detected. Epigenetic and environmental modifiers, including iodine intake, should be considered in families with mutation negative, familial non auto-immune hyperthyroidism (FNAH)

PDF

___

1. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228-38.

2. Leclere J. and Thomas JL. Diffuse nonautoimmune hyperthyroidism. Ann Endocrinol. 1982;43(6):553-68.

3. Nishihara E, Chen CR, Higashiyama T, Mizutori-Sasai Y, Ito M, Kubota S, Amino N, Miyauchi A, Rapoport B. Subclinical Nonautoimmune Hyperthyroidism in a Family Segregates with a Thyrotropin Receptor Mutation with Weakly Increased Constitutive Activity. Thyroid. 2010;20(11):1307-14.

4. Lueblinghoff J, Mueller S, Sontheimer J, Paschke R. Lack of consistent association of thyrotropin receptor mutations invitro activity with the clinical course of patients with sporadic nonautoimmune hyperthyroidism. J Endocrinol Invest. 2010;33(4):228- 33.

5. Hébrant A, van Staveren WC, MaenhautC, DumontJE, LeclèreJ. Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur J Endocrinol. 2011;164(1):1-9.

6. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033-41.

7. Oláh R, Hajós P, Soós Z, Winkler G. De Quervain thyroiditis. Corner points of the diagnosis. Orv Hetil. 2014;155(17):676-80.

8. Kim SK, Lee SM, Transient thyrotoxicosis from thyroiditis induced by sibutramine overdose: a case report. Hum Exp Toxicol. 2013;32(8):890-2.

9. Yoo SS, Hahm JR, Jung JH, Kim HS, Kim S, Chung SI, Jung TS. Lithium-associated thyroiditis. J Med Endocr Pract. 2002;8(3):232-6.

10. Dang AH, Hershman JMAm.Sauter NP, Atkins MB, Mier JW, Lechan RM. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma. Am J Med. 1992;92 (4):441-4.

11. Mueller S, Gozu HI, Bircan R, Jaeschke H, Eszlinger M, Lueblinghoff J, Krohn K, Paschke R. Cases of borderline in vitro constitutive thyrotropin receptor activity: how to decide whether a thyrotropin receptor mutation is constitutively active or not? Thyroid. 2009;19(7):765-73.